U.S. pharmaceutical company expected to release COVID-19 vaccine trial data this month
Posted November 11, 2020 9:11 am.
Last Updated November 11, 2020 1:00 pm.
It’s not just Pfizer at the forefront of vaccine development to fight COVID-19. Another U.S. pharmaceutical company is on the cusp of releasing its trial data.
Massachusetts-based Moderna is expected to have an early look at how effective its vaccine shot is sometime this month, and there’s optimism following Pfizer’s claim to have a 90 per cent effectiveness rate at stopping the virus.
RELATED: Trudeau hopeful Canada will receive COVID-19 vaccines by early 2021
Moderna’s clinical trial involves 40,000 participants split between those vaccinated and those getting a placebo.
Many other companies involved in vaccine trials are sharing data on development.
Bloomberg reports there are at least 11 late-stage studies currently underway, including large-scale trials from Astrazeneca and Johnson & Johnson.
Pfizer’s shot is expected to have a required two months of safety data next week, which — if all turns out well — could get some high-risk individuals vaccinated by December.
Not to be outdone by the American companies, Russia said on Wednesday its vaccine is 92 per cent effective with a trial of 18,000 participants.
